OLR1 and cancer: Immunohistochemistry (IHC) and immunoreactivity scoring results showed that 15-LOX1 and 15-LOX2 were expressed respectively in 55/109 (50.5%) and 58/109 (53.2%) of NSCLCs and the overall expression of both was significantly downregulated in cancer tissues than in normal adjacent tissues (Fig. 3a-b).